Corvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinib

Corvus Pharmaceuticals (CRVS) announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data demonstrated a favorable safety profile and efficacy profile, supporting the ongoing development of soquelitinib for atopic dermatitis and the potential of ITK inhibition as a novel mechanism of action for other immune diseases. Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile. “We are pleased with the early results of our soquelitinib Phase 1 atopic dermatitis clinical trial, which show an attractive potential product profile at the lowest dose we are studying,” said Richard Miller, M.D., co-founder, president and chief executive officer of Corvus. “The data show consistent signs of efficacy, combined with a novel mechanism of action, a convenient oral route of administration and a favorable safety profile.”